This preprint is under consideration at BMC Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Distribution Measurements of Chimeric Antigen Receptor-Modified T Cells Against CD19
xinan Lu
Beijing immunochina
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4721-1684
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Backgroud: The unprecedented efficacy of chimeric antigen receptor (CAR) T-cell immunotherapy of CD19+ B-cell malignancies has opened a new and useful way for the treatment of malignant tumor. Nonetheless, there are still formidable challenges in the field of CAR-T cell therapy, such as the biodistribution of CAR-T cells in vivo.
Methods: We demonstrated the distribution of CAR-T cells in the absence of target cells or with target cells in the mice and the dynamic changes in the patient blood over time after infusion were deteced by qPCR and FACS.
Results: CAR-T cells still proliferated in the mice without target cells and peaked at 2 weeks. However, CAR-T cells did not increase significantly in the presence of target cells within 2 weeks after infusion, but expanded at 6 weeks. In the clinical trial, we found that CAR-T cells peaked at 7-21days after infusion and can last for as long as 510 days in the peripheral blood of patients. Simultaneously, mild side-effects were noted which can be effectively controlled within two months in these patients.
Conclusions: CAR-T cells can expand themselves with or without target cells in mice. CAR-T cells can persistence for a long time in patients.
Keywords
CAR-T, qPCR, Biodistribution, Tissue, Blood
Figure 1
Figure 2
Figure 3
Figure 4
This is a list of supplementary files associated with this preprint. Click to download.
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 17 Sep, 2020
No community comments so far
Review #2 received
Received 22 Nov, 2020
Editorial decision: Major revision
On 22 Nov, 2020
Reviewer #3 agreed
On 09 Nov, 2020
Reviewer #2 agreed
On 04 Nov, 2020
Review #1 received
Received 12 Oct, 2020
Reviewer #1 agreed
On 01 Oct, 2020
Reviewers invited
Invitations sent on 20 Sep, 2020
Editor assigned
On 17 Sep, 2020
Submission checks complete
On 15 Sep, 2020
Editor invited
On 14 Sep, 2020
First submitted
On 30 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
This preprint is under consideration at BMC Cancer. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Distribution Measurements of Chimeric Antigen Receptor-Modified T Cells Against CD19
xinan Lu
Beijing immunochina
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4721-1684
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Review
Version 1
Posted 17 Sep, 2020
No community comments so far
Review #2 received
Received 22 Nov, 2020
Editorial decision: Major revision
On 22 Nov, 2020
Reviewer #3 agreed
On 09 Nov, 2020
Reviewer #2 agreed
On 04 Nov, 2020
Review #1 received
Received 12 Oct, 2020
Reviewer #1 agreed
On 01 Oct, 2020
Reviewers invited
Invitations sent on 20 Sep, 2020
Editor assigned
On 17 Sep, 2020
Submission checks complete
On 15 Sep, 2020
Editor invited
On 14 Sep, 2020
First submitted
On 30 Aug, 2020
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Backgroud: The unprecedented efficacy of chimeric antigen receptor (CAR) T-cell immunotherapy of CD19+ B-cell malignancies has opened a new and useful way for the treatment of malignant tumor. Nonetheless, there are still formidable challenges in the field of CAR-T cell therapy, such as the biodistribution of CAR-T cells in vivo.
Methods: We demonstrated the distribution of CAR-T cells in the absence of target cells or with target cells in the mice and the dynamic changes in the patient blood over time after infusion were deteced by qPCR and FACS.
Results: CAR-T cells still proliferated in the mice without target cells and peaked at 2 weeks. However, CAR-T cells did not increase significantly in the presence of target cells within 2 weeks after infusion, but expanded at 6 weeks. In the clinical trial, we found that CAR-T cells peaked at 7-21days after infusion and can last for as long as 510 days in the peripheral blood of patients. Simultaneously, mild side-effects were noted which can be effectively controlled within two months in these patients.
Conclusions: CAR-T cells can expand themselves with or without target cells in mice. CAR-T cells can persistence for a long time in patients.
Figure 1
Figure 2
Figure 3
Figure 4